9 Apr 2021
BOLD-100 MoA Research to Be Presented at the AACR Annual Meeting
Author: admintech | Filed under: Press ReleasePHILADELPHIA, April 9, 2021 /PRNewswire/ — Bold Therapeutics, a clinical-stage biopharmaceutical company developing BOLD-100, a first-in-class anti-cancer agent, announced that Sandra Van Schaeybroeck, PhD (Queen’s University Belfast) will be presenting research supporting BOLD-100 as a…